A Phase 3 Study of Orelabrutinib to Delay Disability Progression in Patients with Non‑Active Secondary Progressive Multiple Sclerosis
- Substances:–
France- Participants:18–64 years
- Sponsor:Zenas Biopharma (USA) LLC
Rare diseases
Investigational molecules
Locations
1 Rue De Germont, Bp 96031, 76031 Rouen, France
Centre Hospitalier Universitaire Rouen in Rouen, France specialises in clinical trials of conditions such as Dermatitis atopic, Hidradenitis, Dementia Alzheimer's type, Non-small cell lung cancer, and other specialisations. This site conducts important research.
The medical center is at the forefront of research in immune system disorders, focusing on innovative strategies for managing conditions like sarcoidosis. The center's work in this area aims to enhance remission maintenance strategies, particularly following the administration of TNF-alpha antagonists.
By exploring withdrawal strategies of infliximab, the center contributes to personalized treatment plans that optimize patient outcomes.
Specializing in non-small cell lung cancer (NSCLC), the center is pioneering trials to evaluate the efficacy of pembrolizumab in combination with chemotherapy. This research is crucial for advancing treatment protocols for stage IV NSCLC patients.
The center's efforts are directed towards improving survival rates and quality of life for patients with advanced lung cancer.
In the realm of gastroenterology, the center is conducting groundbreaking research on severe irritable bowel syndrome (IBS). The focus is on the efficacy of fecal microbiota transplantation (FMT) delivered via capsules.
This innovative approach aims to provide relief for patients with IBS who have not responded to conventional treatments.
The center is advancing the treatment of chronic pulmonary aspergillosis through comparative studies of itraconazole and nebulised Ambisome®. This research is pivotal for patients with compromised immune systems.
By refining therapeutic approaches, the center aims to improve clinical and radiological outcomes for affected patients.
In nephrology, the center is exploring innovative treatments for renal failure and gout flares in patients with chronic kidney disease. The focus is on the use of anakinra versus prednisone.
This research is crucial for developing safer and more effective treatment protocols for patients with renal complications.
The center is at the cutting edge of research in alcohol-related liver disease, focusing on the safety and efficacy of GSK4532990. This work is essential for improving liver function and patient outcomes.
Through rigorous trials, the center aims to establish new standards of care for liver disease management.
In the field of endocrinology, the center is investigating the role of vitamin C in reducing the incidence of complex regional pain syndrome (CRPS) post-surgery. This research is pivotal for enhancing recovery and reducing complications.
The center's work is instrumental in developing preventive strategies for post-surgical complications.
Clinical trials currently enrolling participants at this site.
France
France
France
France
France
France
France
France
France
France
France
FranceMove up to Verified & featured: your own description, photos and phone number on this page, and top placement on every trial you run.
See the offer for sitesTell us about your condition – we search every trial in Europe and connect you with the right site.